- Home
- BIVI vs CASI Comparison
BIVI vs CASI Comparison
Compare BIVI & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIVI
- CASI
- Stock Information
- Founded
- BIVI 2013
- CASI 1991
- Country
- BIVI United States
- CASI China
- Employees
- BIVI N/A
- CASI N/A
- Industry
- BIVI Biotechnology: Pharmaceutical Preparations
- CASI Biotechnology: Pharmaceutical Preparations
- Sector
- BIVI Health Care
- CASI Health Care
- Exchange
- BIVI Nasdaq
- CASI Nasdaq
- Market Cap
- BIVI 49.8M
- CASI 58.8M
- IPO Year
- BIVI N/A
- CASI 1996
- Fundamental
- Price
- BIVI $1.48
- CASI $2.45
- Analyst Decision
- BIVI Strong Buy
- CASI Strong Buy
- Analyst Count
- BIVI 1
- CASI 1
- Target Price
- BIVI $30.00
- CASI $6.00
- AVG Volume (30 Days)
- BIVI 596.3K
- CASI 14.6K
- Earning Date
- BIVI 02-11-2025
- CASI 03-27-2025
- Dividend Yield
- BIVI N/A
- CASI N/A
- EPS Growth
- BIVI N/A
- CASI N/A
- EPS
- BIVI N/A
- CASI N/A
- Revenue
- BIVI N/A
- CASI $22,055,000.00
- Revenue This Year
- BIVI N/A
- CASI N/A
- Revenue Next Year
- BIVI N/A
- CASI $134.79
- P/E Ratio
- BIVI N/A
- CASI N/A
- Revenue Growth
- BIVI N/A
- CASI N/A
- 52 Week Low
- BIVI $1.04
- CASI $2.05
- 52 Week High
- BIVI $33.10
- CASI $7.67
- Technical
- Relative Strength Index (RSI)
- BIVI 32.72
- CASI 42.71
- Support Level
- BIVI $1.45
- CASI $2.48
- Resistance Level
- BIVI $1.88
- CASI $2.65
- Average True Range (ATR)
- BIVI 0.16
- CASI 0.17
- MACD
- BIVI -0.01
- CASI 0.03
- Stochastic Oscillator
- BIVI 5.08
- CASI 39.47
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.